Clinical Study Data Request Registered Users, Please Login

Scroll down the list of studies provided below. Studies are listed by study medicine in alphabetical order. Alternatively you can browse the list of studies using the search function.

To select studies and submit a research proposal or enquiry, go back to the Home page and select View and submit.

This takes you back to the previous page to enable you to view studies from a different sponsor.

Select medicine, medical condition or phase from the drop down boxes. This searches all the available clinical studies. Selecting from more than one drop down box will “and” the criteria.

Find by:


Alternatively search for studies using the Astellas Clinical Study Identification Number or study title by entering text and clicking search.

 

41 found

Click the study title to find more information about the study.

ASTELLAS-CDP870-275-11-001
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Patients With Early-stage Rheumatoid Arthritis Who Are Naïve to Methotrexate and Have Poor Prognostic Factors

Medicine: certolizumab pegol, Condition: Rheumatoid Arthritis, Phase: 3, Clinical Study ID: CDP870-275-11-001, Sponsor: Astellas
ASTELLAS-9785-CL-0401
A Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to Enzalutamide (MDV3100) and Monitor Its Safety in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy

Medicine: enzalutamide, Condition: Castration-resistant prostate cancer, Phase: 4, Clinical Study ID: 9785-CL-0401, Sponsor: Astellas
ASTELLAS-OSI-774-302
A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors

Medicine: erlotinib, Condition: Non-small cell lung cancer, Phase: 3, Clinical Study ID: OSI-774-302, Sponsor: Astellas
ASTELLAS-1941-CL-0004
A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Subjects with Type 2 Diabetes Mellitus

Medicine: ipragliflozin, Condition: Diabetes Mellitus, Type 2, Phase: 2, Clinical Study ID: 1941-CL-0004, Sponsor: Astellas
ASTELLAS-1941-CL-0005
Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone

Medicine: ipragliflozin, Condition: Diabetes Mellitus, Type 2, Phase: 2, Clinical Study ID: 1941-CL-0005, Sponsor: Astellas
ASTELLAS-1941-CL-0072
Long-term Study of ASP1941 — Long-term Study in Patients with Type 2 Diabetes Mellitus with Decreased Renal Function (Japanese) —

Medicine: ipragliflozin, Condition: Diabetes Mellitus, Type 2, Phase: 3, Clinical Study ID: 1941-CL-0072, Sponsor: Astellas
ASTELLAS-1941-CL-0105
Phase III Study of ASP1941 –A Phase III, Randomized, Double-Blind, Placebo-controlled, Monotherapy Study to Assess the Efficacy, Safety, and Tolerability of ASP1941 in Japanese Patients with Type 2 Diabetes Mellitus–

Medicine: ipragliflozin, Condition: Diabetes Mellitus, Type 2, Phase: 3, Clinical Study ID: 1941-CL-0105, Sponsor: Astellas
ASTELLAS-1941-CL-0106
A Phase 3 Study to Assess the Efficacy and Safety of ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone

Medicine: ipragliflozin, Condition: Diabetes Mellitus, Type 2, Phase: 3, Clinical Study ID: 1941-CL-0106, Sponsor: Astellas
ASTELLAS-1941-CL-0107
A Phase III Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination with Pioglitazone in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Alone

Medicine: ipragliflozin, Condition: Diabetes Mellitus, Type 2, Phase: 3, Clinical Study ID: 1941-CL-0107, Sponsor: Astellas
ASTELLAS-1941-CL-0108
Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination with an a-Glucosidase Inhibitor in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with an a-Glucosidase Inhibitor Alone

Medicine: ipragliflozin, Condition: Diabetes Mellitus, Type 2, Phase: 3, Clinical Study ID: 1941-CL-0108, Sponsor: Astellas
First Previous 1 2 3 4 5 Next Last